N-methyl-D-aspartate receptor subunit zeta-1 (GRIN1) (GluN1)

The Human NMDA receptor glycine-binding site is a critical regulatory locus located on the GluN1 (GRIN1) subunit of the N-methyl-D-aspartate (NMDA) receptor complex. Unlike most ligand-gated channels that require a single neurotransmitter, the NMDA receptor is unique in requiring the simultaneous binding of two co-agonists: glutamate at the GluN2 subunit and glycine (or D-serine) at the GluN1 subunit to initiate ion conduction. This site is termed strychnine-insensitive to distinguish it from the inhibitory glycine receptor. It plays a fundamental role in synaptic plasticity, which is the cellular basis for learning and memory formation. In clinical medicine, the glycine-binding site is a major therapeutic target for neuropsychiatric disorders. Hypofunction of NMDA receptors, often linked to inadequate glycine site occupancy, is a leading hypothesis in the pathophysiology of schizophrenia, prompting the development of glycine transporters inhibitors and glycine site agonists like D-cycloserine. Conversely, over-activation of this site is implicated in excitotoxic neuronal death during stroke and chronic pain states, leading to the investigation of glycine site antagonists as neuroprotective agents. Because the glycine site modulates the receptor's response to glutamate without directly opening the channel itself, it offers a 'fine-tuning' mechanism that is often better tolerated than direct pore-blocking drugs like ketamine.

Other names

NMDA receptor glycine-binding siteStrychnine-insensitive glycine siteGlutamate receptor ionotropic NMDA 1NR1NMDA receptor co-agonist site

The glycine-binding site acts as an obligatory co-agonist site; binding of glycine or D-serine to the GluN1 subunit, alongside glutamate binding to the GluN2 subunit, is required for the NMDA receptor ion channel to open and allow cation influx.